Insmed, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$40.1M
Doctors Paid
12,303
Transactions
89,291
2024 Total
$8.3M
Payment Breakdown by Category
Research$31.5M (78.6%)
Consulting$2.8M (7.1%)
Food & Beverage$1.6M (3.9%)
Travel$713,447 (1.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $31.5M | 16,267 | 78.6% |
| Consulting Fee | $2.8M | 1,324 | 7.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.7M | 915 | 4.3% |
| Food and Beverage | $1.6M | 61,764 | 3.9% |
| Grant | $1.4M | 28 | 3.4% |
| Travel and Lodging | $713,447 | 2,015 | 1.8% |
| Education | $231,747 | 6,881 | 0.6% |
| Space rental or facility fees (teaching hospital only) | $153,190 | 97 | 0.4% |
Payments by Type
Research
$31.5M
16,267 transactions
General
$8.6M
73,024 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | $14.2M | 9 | 4,718 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | $5.6M | 3 | 6,834 |
| A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) | $4.8M | 0 | 2,224 |
| Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study | $1.5M | 0 | 335 |
| A Phase 2a, Single-Blind, Placebo-Controlled, Parallel-Group Study to Assess Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis | $1.1M | 0 | 264 |
| ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) | $1.0M | 0 | 725 |
| ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) | $892,631 | 0 | 504 |
| A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension | $407,213 | 0 | 92 |
| A Randomized, Open-label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) That Are Refractory to Treatment | $347,039 | 0 | 101 |
| A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease | $279,863 | 1 | 92 |
| INS1007-102 | $274,849 | 0 | 24 |
| An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium Avium Complex (MAC) That Are Refractory to Treatment | $267,005 | 0 | 114 |
| An Open-Label Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension | $209,977 | 0 | 49 |
| A Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH) | $159,774 | 0 | 25 |
| An Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | $121,797 | 6 | 48 |
| OHSU Biobank: The Oregon nontuberculous mycobacteria (NTM) cohort; immune correlates of pulmonary NTM disease progression | $108,653 | 0 | 3 |
| Insmed BIRCH Study | $49,295 | 8 | 51 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Joseph Khabbaza, M.d, M.D | Pulmonary Disease | Akron, OH | $323,640 | $0 |
| David Griffith, Md, MD | Pulmonary Disease | Denver, CO | $237,010 | $0 |
| Dr. Colin Swenson, M.d, M.D | Pulmonary Disease | Atlanta, GA | $185,468 | $0 |
| Juan Wisnivesky, Md, MD | Internal Medicine | New York, NY | $162,668 | $0 |
| Dr. Andrew Dold, D.o, D.O | Infectious Disease | Dacula, GA | $162,475 | $0 |
| Anas Hadeh, Md, MD | Pulmonary Disease | Weston, FL | $149,984 | $0 |
| Juzar Ali, Md.,Frcp., Fccp(C), MD.,FRCP., FCCP(C) | Pulmonary Disease | New Orleans, LA | $144,936 | $0 |
| Charles Daley, Md, MD | Critical Care Medicine | Denver, CO | $137,235 | $0 |
| Fernando Holguin, Md, MD | Pulmonary Disease | Aurora, CO | $131,083 | $0 |
| Wendi Drummond, D.o, D.O | Infectious Disease | Portland, OR | $127,425 | $0 |
| Dr. Pamela Mcshane, M.d, M.D | Internal Medicine | Tyler, TX | $126,503 | $0 |
| Patrick Flume, Md, MD | Pulmonary Disease | Charleston, SC | $118,549 | $0 |
| Abhijit Raval, Md, MD | Internal Medicine | Anderson, SC | $115,875 | $0 |
| Wael El Maraachli, Md, MD | Pulmonary Disease | San Diego, CA | $114,402 | $0 |
| Nicole Lapinel, M.d, M.D | Student in an Organized Health Care Education/Training Program | New Orleans, LA | $113,541 | $0 |
| Brian Furukawa, Md, MD | Pulmonary Disease | Temple, TX | $88,838 | $0 |
| David Kamelhar, Md, MD | Pulmonary Disease | New York, NY | $85,674 | $0 |
| Deborah Levine, Md, MD | Critical Care Medicine | Stanford, CA | $78,479 | $0 |
| George Solomon | Critical Care Medicine | Birmingham, AL | $71,306 | $0 |
| Dr. Julie Philley, Md, MD | Internal Medicine | Tyler, TX | $65,269 | $0 |
| Mark Metersky, Md, MD | Pulmonary Disease | Farmington, CT | $62,819 | $0 |
| Kevin Winthrop, Md, MD | Infectious Disease | Portland, OR | $61,540 | $0 |
| Mouhammed Rihawi, Md, MD | Pulmonary Disease | Milwaukee, WI | $60,807 | $0 |
| Shannon Kasperbauer, Md, MD | Infectious Disease | Denver, CO | $59,394 | $0 |
| Chakrapol Sriaroon, M.d, M.D | Internal Medicine | Tampa, FL | $56,238 | $0 |
About Insmed, Inc.
Insmed, Inc. has made $40.1M in payments to 12,303 healthcare providers, recorded across 89,291 transactions in the CMS Open Payments database. In 2024, the company paid $8.3M. The top product by payment volume is Arikayce ($23.0M).
Payments were distributed across 138 medical specialties. The top specialty by payment amount is Pulmonary Disease ($3.1M to 2,478 doctors).
Payment categories include: Food & Beverage ($1.6M), Consulting ($2.8M), Research ($31.5M), Travel & Lodging ($713,447).
Insmed, Inc. is associated with 2 products in the CMS Open Payments database.